VERV Verve Therapeutics, Inc.: institutional ownership and insider trading
3 funds reported holding $7.44M of Verve Therapeutics, Inc. in their latest 13F filings; in Q1 2026 funds net bought $0, with 0 new positions and 1 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
VERV revenue and earnings
- Quarter ended Mar 31, 2025: revenue n/a, net income −$31.0M, EPS -0.35
- Quarter ended Dec 31, 2024: revenue n/a, net income −$50.0M, EPS -0.58
- Quarter ended Sep 30, 2024: revenue n/a, net income −$50.1M, EPS -0.59
- Quarter ended Jun 30, 2024: revenue n/a, net income −$49.8M, EPS -0.59
Largest institutional holders of VERV
- Nuveen Asset Management, LLC — $7.42M
- Sandy Spring Bank — $11.9K
- Lindbrook Capital, LLC — $4.25K
Recent VERV insider trades
- Apr 2, 2025: Ashe Andrew D. sold 2,681 shares ($11.1K)
- Apr 2, 2025: Politi Jason sold 3,235 shares ($13.4K)
- Apr 2, 2025: Dorval Allison sold 3,350 shares ($13.9K)
- Apr 2, 2025: Lister Troy sold 2,189 shares ($9.08K)
5%+ owners
- Pentwater Capital Management LP: 7.5% (Schedule 13G, filed Aug 14, 2025)
- BlackRock, Inc.: 7.0% (Schedule 13G/A, filed Apr 17, 2025)